May 5, 2019 / 9:37 PM / 15 days ago

BRIEF-Avexis Presented Robust Data At AAN Demonstrating Efficacy Of Zolgensma In Broad Spectrum Of Spinal Muscular Atrophy Patients

May 5 (Reuters) - Avexis:

* AVEXIS SAYS NEW INTERIM DATA FROM STR1VE IN SMA TYPE 1 CONTINUED TO SHOW SIGNIFICANT MILESTONE ACHIEVEMENT CONSISTENT WITH PHASE 1 START TRIAL

* AVEXIS PRESENTED ROBUST DATA AT AAN DEMONSTRATING EFFICACY OF ZOLGENSMA® IN BROAD SPECTRUM OF SPINAL MUSCULAR ATROPHY (SMA) PATIENTS

* AVEXIS-NEW INTERIM DATA FROM STR1VE IN SMA TYPE 1 CONTINUED TO SHOW PROLONGED EVENT-FREE SURVIVAL, INCREASES IN MOTOR FUNCTION

* AVEXIS-INTERIM DATA FROM ONGOING TRIALS OF ZOLGENSMA SHOW POSITIVE RESULTS ACROSS BROAD SPECTRUM OF PATIENTS WITH SPINAL MUSCULAR ATROPHY

* RPT-AVEXIS SAYS INTERIM DATA REPORTED FOR FIRST TIME FROM SPR1NT IN PRE-SYMPTOMATIC SMA SHOWED AGE-APPROPRIATE MOTOR MILESTONE ACHIEVEMENT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below